When administered in the early stages, the antibodies lecanemab and donanemab can remove amyloid-beta deposits from the brain, thereby slowing the progression of Alzheimer’s disease. The two Alzheimer’s antibodies have now been in use for over a year. Özgür Onur, MD, head of the Neurological Intensive Care Unit, University Hospital Cologne, Cologne, Germany, discussed how the treatments are performing in clinical practice during an online press conference hosted by the German Society for Neurology (DGN) as part of Neuroweek.“For the first time, we have medications with which we can influence the course of the disease. This is a decisive step upon which further development can build,” emphasized Onur, who is also the spokesperson for the DGN’s Commission on Dementia. Patients and their families can expect the antibody therapy to slow the progression of the disease. Onur referred to a “braking effect”; perhaps “stabilization may also be achieved at times.”The clinical trials for lecanemab and donanemab showed a statistically significant slowing of cognitive and functional decline. For lecanemab, the relative slowing over 18 months was approximately 27%. For donanemab, the rate of slowing over the same period was 22% in the overall study population and 35% in patients with low-to-moderate tau pathology. However, it is not yet fully clear how the slowing observed in the studies will play out over longer periods of time.Imaging Abnormalities Less Common Than in Approval Trials“Feedback to date from German memory clinics is encouraging,” Onur reported. No new safety signals or serious side effects were observed. Concerns about serious side effects had been high at the start of treatment. The focus has been — and remains — on amyloid-related imaging abnormalities, which can appear on MRI as brain swelling or signs of bleeding. Such changes are often asymptomatic, but they can also cause serious complications.As Onur reported, international observational studies have so far shown no evidence of new safety signals beyond the known risks — and amyloid-related imaging abnormalities occurred less frequently than in the clinical trials. “One reason for this is certainly the careful examinations conducted before and during treatment, with the goal of minimizing risks,” said Onur.Antibody therapy requires careful patient selection, an individualized risk assessment, and regular MRI monitoring. Accordingly, it is administered in specialized centers and practices.Why Germany’s Federal Joint Committee (G-BA) Found No Added BenefitThe decision by the G-BA that an added benefit had “not been demonstrated” for lecanemab and donanemab sparked considerable debate. But the committee’s requirements for assessing added benefit differ from those used in clinical trials. The trials supporting approval were not designed to determine whether either drug offers added benefit over a comparator therapy. For its assessment, the G-BA included only patients who met the narrower European approval criteria and evaluated patients with mild cognitive impairment separately from those with mild dementia because the appropriate comparator therapies differed between the groups.Due to the reduced number of patients, the previously significant efficacy effect weakened considerably. The G-BA’s assessment does not affect approval; however, it serves as the basis for negotiations regarding reimbursement amounts. It remains to be seen how this will affect access to antibody therapies in the long term. “One can understand the methodological requirements of the benefit assessment and still debate whether the application of these criteria was appropriate,” commented Onur. Furthermore, a question arises as to whether they accurately reflect clinical progress in this case.The Future of Treatment“After 1 year, it’s clear that those we treat very early on seem to benefit more from the therapy than those whose disease is already more advanced at the start of treatment. The trend strongly pointed to the principle: the earlier, the better,” emphasized Onur.Blood biomarkers that provide evidence of changes in the brain typical of Alzheimer’s disease show great promise for early detection. These include, in particular, phosphorylated tau 217. Effective blood tests could simplify diagnosis in the future and help identify people with Alzheimer’s disease even earlier.However, a blood test alone cannot replace a comprehensive clinical diagnosis. For this reason, the blood tests are also not suitable for broad-scale screening of the asymptomatic population. “A positive biomarker result does not necessarily mean that the person in question will develop dementia at some point in their life,” explained Onur.Moreover, it is not yet sufficiently clear what therapeutic implications such a finding should have for people without cognitive symptoms. The DGN therefore currently recommends the use of these tests primarily for targeted diagnostic evaluation of people with existing cognitive symptoms in specialized facilities — and not as a general preventive screening.Treating Before the First Symptoms Appear?In the future, blood tests and PET scans could enable treatment to begin even earlier, because biological changes typical of Alzheimer’s disease occur many years before the first noticeable memory impairments appear. Current clinical trials, such as AHEAD 3-45 with lecanemab and TRAILBLAZER-ALZ 3 with donanemab, are therefore investigating whether people who do not yet show cognitive impairment — but in whom corresponding signs are already detectable in the brain — could also benefit from antibody therapies.If Alzheimer’s disease can be treated at a stage when those affected do not yet have any symptoms, that would represent further progress. However, Onur does not expect the decisive breakthrough to come from a single therapy but from the gradual refinement and combination of various treatment approaches. He said, “We will likely not be able to treat Alzheimer’s with a single drug.”This story was translated from Medscape’s German edition.
Lecanemab and Donanemab After 1 Year: Early Lessons
Full Article
Original Source
Read the full article at Medscape →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.